Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT), an eyecare technology company, has announced its participation in Citi's 2025 Unplugged MedTech and Life Sciences Access Day in New York. The company, which specializes in developing innovative interventional technologies for eye care, will deliver a presentation on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET.
Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.sightsciences.com. This presentation represents an opportunity for stakeholders to gain insights into the company's developments and strategies in transformative eye care solutions.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SGHT declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day, in New York, NY.
Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.
© 2025 Sight Sciences. All rights reserved.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
FAQ
When is Sight Sciences (SGHT) presenting at Citi's 2025 Unplugged MedTech conference?
How can investors watch Sight Sciences' (SGHT) presentation at the Citi 2025 conference?
What type of technologies does Sight Sciences (SGHT) develop?
Where is the Citi 2025 Unplugged MedTech conference featuring SGHT being held?
